REGN

Regeneron Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Did you know?

Profit margin of 31.4% — that's well above average.

Current Price

$766.02

+2.60%

GoodMoat Value

$1382.84

80.5% undervalued

Profile

Valuation (TTM)

Market Cap$80.51B

P/E17.87

EV$71.51B

P/B2.58

Shares Out105.10M

P/Sales5.61

Revenue$14.34B

EV/EBITDA12.82

Regeneron Pharmaceuticals Inc (REGN) Company Profile

GoodMoat Analysis

Based on data as of March 26, 2026

Regeneron is a leading biotechnology company with a strong moat built on proprietary technology and blockbuster drugs, but faces significant concentration and growth risks. Its current valuation appears modest, with a P/E of 17.5 and a free cash flow yield of 5.2%, which may be attractive if its pipeline can offset key drug dependencies.

Read full analysis

Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. It primarily creates monoclonal antibody treatments, which are lab-made proteins that mimic the immune system's ability to fight pathogens. Its customers are patients, but its revenue comes from sales to healthcare providers and, significantly, from partnerships with larger pharmaceutical companies. The company's moat, assessed via the framework, is strong in areas like Proprietary Technology (criterion 9) through its VelocImmune platform for antibody creation, and Strategic Partnerships (criterion 7) like its long-standing collaboration with Sanofi for key drugs. However, it scores lower on criteria like Low Disruption Risk, given the constant competitive threat in biotech. Key risks are severe and align with High Confidence Red Flags. The business shows high customer and product concentration, with a significant portion of revenue reliant on a few drugs like Eylea and Dupixent, and on its partnership with Sanofi. Furthermore, the current revenue growth of 2.5% YoY is a potential Growth Deceleration flag, especially if the stock price implicitly expects a return to higher growth. For a value investor, the interest lies in the combination of a profitable, moat-protected business trading at a reasonable P/E of 17.5 and generating solid free cash flow (5.2% yield). The caution is whether the company's pipeline can successfully diversify revenue before facing increased competition for its core products. Analysis based on data as of 2024-05-15.

REGN Company Information

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies.

We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

New York, USA

REGN Key Officers

Key officers data coming soon

REGN Company Profile

Regeneron Pharmaceuticals Inc (REGN) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in New York, USA.

Market cap is $80.51B. There are 105.1M shares outstanding. Dividend yield is 0.46%.

See the full Regeneron Pharmaceuticals Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if REGN is a good investment.